Hepatic Encephalopathy Treatment Guidelines

Introduction to Treatment

The American Association for the Study of Liver Diseases recommends lactulose as the first-line treatment for hepatic encephalopathy, with a recommended dosage of 30-45 mL (20-30 g) orally every 1-2 hours until the patient has at least 2 bowel movements per day, then titrated to achieve 2-3 soft stools daily 1, 2

Identify and manage precipitating factors including gastrointestinal bleeding, infection, constipation, excessive protein intake, dehydration, renal dysfunction, electrolyte imbalance, psychoactive medications, and acute hepatic injury 3, 4
Begin lactulose at 30-45 mL (20-30 g) orally every 1-2 hours until the patient has at least 2 bowel movements daily 5, 6
After initial response, titrate lactulose to maintain 2-3 soft stools per day 5, 1
For patients unable to take oral medications, administer lactulose via nasogastric tube 5
For severe HE (West-Haven criteria grade ≥3) or when oral/nasogastric administration isn't possible, use lactulose enema (300 mL lactulose in 700 mL water) 3-4 times daily until clinical improvement 5

Rifaximin (550 mg twice daily or 400 mg three times daily) can be added to lactulose for better outcomes 5
Combination therapy with rifaximin and lactulose shows better recovery from HE (76% vs. 44%) and shorter hospital stays (5.8 vs. 8.2 days) compared to lactulose alone 5

Oral branched-chain amino acids (BCAA) at 0.25 g/kg/day can be used as an alternative or additional agent 5, 3
Intravenous L-ornithine L-aspartate (LOLA) at 30 g/day can be used as an alternative or additional agent 5, 1
Intravenous albumin at 1.5 g/kg/day until clinical improvement or for maximum 10 days can be used as an alternative or additional agent 5, 4
Polyethylene glycol (4 liters orally) can be used as an alternative to non-absorbable disaccharides 5

Lactulose reduces intestinal pH through bacterial degradation to acetic and lactic acids 5
Lactulose increases lactobacillus count, which doesn't produce ammonia 5
Lactulose converts ammonia to non-absorbable ammonium 5
Neomycin and metronidazole are not recommended as first-line agents due to significant side effects, including intestinal malabsorption, nephrotoxicity, ototoxicity, and peripheral neuropathy 5, 1

Oral LOLA supplementation is ineffective, only the intravenous form shows benefit 1, 7
Patients with TIPS (transjugular intrahepatic portosystemic shunt) may develop HE that doesn't respond well to standard therapy; in these cases, shunt diameter reduction may be necessary 1, 8